These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19032230)

  • 41. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.
    Walker S; Burch J; McKenna C; Wright K; Griffin S; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():13-21. PubMed ID: 21609649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].
    Drugs Today (Barc); 2008 Jun; 44 Suppl 3():1-43. PubMed ID: 19093041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
    Rely K; McQuire SE; Alexandre PK; Escudero GS
    Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multisite randomized trial of the effects of physician education and organizational change in chronic asthma care: cost-effectiveness analysis of the Pediatric Asthma Care Patient Outcomes Research Team II (PAC-PORT II).
    Sullivan SD; Lee TA; Blough DK; Finkelstein JA; Lozano P; Inui TS; Fuhlbrigge AL; Carey VJ; Wagner E; Weiss KB
    Arch Pediatr Adolesc Med; 2005 May; 159(5):428-34. PubMed ID: 15867115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Asthma treatment guidelines: how do we measure up?
    Navarro RP
    Am J Manag Care; 2005 Nov; 11(14 Suppl):S422-6; quiz S427-33. PubMed ID: 16300463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
    Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.
    Sullivan SD; Buxton M; Andersson LF; Lamm CJ; Liljas B; Chen YZ; Pauwels RA; Weiss KB
    J Allergy Clin Immunol; 2003 Dec; 112(6):1229-36. PubMed ID: 14657888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
    Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
    Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salmeterol/fluticasone propionate combination product in asthma. An evaluation of its cost effectiveness vs fluticasone propionate.
    Pharmacoeconomics; 1999; 16 Suppl 2():i-viii, 1-34. PubMed ID: 10724799
    [No Abstract]   [Full Text] [Related]  

  • 50. Does the current stepwise approach to asthma pharmacotherapy encourage over-treatment?
    O'Byrne PM; Reddel HK; Colice GL
    Respirology; 2010 May; 15(4):596-602. PubMed ID: 20384969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of current and optimal treatment for adult asthma.
    Simonella L; Marks G; Sanderson K; Andrews G
    Intern Med J; 2006 Apr; 36(4):244-50. PubMed ID: 16640742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Questioning the economic evaluation of omalizumab.
    Revicki D; Brown R; Dale P
    J Allergy Clin Immunol; 2008 Jun; 121(6):1514; author reply 1514-5. PubMed ID: 18395781
    [No Abstract]   [Full Text] [Related]  

  • 53. [Pharmacotherapeutical management of bronchial asthma].
    Leont'ev SL; Mikhaĭlov VG; Nevzorova VP; Sadovnikova RV; Shabashov AF; Lugovkina TK; Leshchenko IV; Bel'tiukov EK; Lebedeva MK
    Klin Med (Mosk); 1998; 76(10):39-41. PubMed ID: 9865016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current asthma management: the performance gap and economic consequences.
    Stoloff S
    Am J Manag Care; 2000 Oct; 6(17 Suppl):S918-25; discussion S925-9. PubMed ID: 11184563
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Asthma outcome measures.
    Shen J; Johnston M; Hays RD
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):447-53. PubMed ID: 21831026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.
    Yamamoto D; Campbell JD
    Autoimmune Dis; 2012; 2012():784364. PubMed ID: 23304459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal.
    Azharuddin M; Adil M; Khan RA; Ghosh P; Kapur P; Sharma M
    Osteoporos Sarcopenia; 2020 Jun; 6(2):39-52. PubMed ID: 32715093
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
    Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Economic evidence for nonpharmacological asthma management interventions: A systematic review.
    Crossman-Barnes CJ; Peel A; Fong-Soe-Khioe R; Sach T; Wilson A; Barton G
    Allergy; 2018 Jun; 73(6):1182-1195. PubMed ID: 29105788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.
    Takura T; Takei T; Nitta K
    Sci Rep; 2017 Apr; 7():46036. PubMed ID: 28387313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.